Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lee’s Pharmaceutical Holdings Limited ( (HK:0950) ) has provided an announcement.
Lee’s Pharmaceutical Holdings Limited reported a 5.5% increase in revenue for the first half of 2025, driven by strong sales in its product portfolio, particularly in rare disease and specialty products like Treprostinil Injection and Bredinin. Despite a slight decrease in gross profit margin due to a strategic shift towards a more diversified product portfolio, the company achieved a 2.7% increase in gross profit. This growth reflects the company’s adaptation to market demands and its focus on stabilizing its financial performance amid changing industry dynamics.
The most recent analyst rating on (HK:0950) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Lee’s Pharmaceutical Holdings Limited stock, see the HK:0950 Stock Forecast page.
More about Lee’s Pharmaceutical Holdings Limited
Lee’s Pharmaceutical Holdings Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company focuses on developing and selling a diverse range of pharmaceutical products, including rare disease and specialty products, proprietary, generic, and licensed-in products. It is actively involved in the Volume-Based Procurement (VBP) program, which influences its product portfolio and market strategy.
Average Trading Volume: 2,665,358
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.19B
Learn more about 0950 stock on TipRanks’ Stock Analysis page.